Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog (NYSE:NVO)

Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog (NYSE:NVO)

Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven selloff. Find out why NVO stock is a buy.

Should You Dump Eli Lilly's Shares After This Setback?

Key PointsEli Lilly's oral GLP-1 candidate, orforglipron, won't earn approval as fast as the company expected.Meanwhile, a notable competitor is making headway in this market.Even with this setback, Eli Lilly should remain the leader in the weight loss space. 10 stocks we like better than Eli Lilly › Competition in the weight loss market is heating up. The two leaders, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), have robust pipelines, wi…

Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

New York, Jan 24, 2026, 10:05 EST — Market closed Eli Lilly and Co shares fell on Friday, breaking a brief streak of gains as investors refocused on the ongoing battle in the obesity drug sector that has driven the stock’s recent volatility. The shares closed 2.12% lower at $1,064.29. (Investing.com) The decline is significant since Lilly’s valuation hinges largely on its diabetes and weight-loss business, along with its ability to expand access…